News und Analysen

Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning. 

The big dip came

Buying low-priced growth stocks ($10 or below) can be risky. Companies with bargain-basement share prices tend to have weak balance sheets, highly uncertain outlooks, and limited financing

Michael Thomsen is the author of Cage Kings: How an Unlikely Group of Moguls, Champions, and Hustlers Transformed the UFC Into a $10 Billion Industry.

Motley Fool host Ricky Mulvey caught up with

What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be

What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own

Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics

Trupanion's (NASDAQ: TRUP) stock price had plummeted 15.6% this week as of Friday morning at 9:45 a.m. ET, according to S&P Global Market Intelligence. Trupanion was trading at about $22 per share

Shares of Surmodics (NASDAQ: SRDX) were up by 24.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The medical device company's stock closed last

Consumers know CVS Health (NYSE: CVS) for its pharmacy retail stores, but the overall company is much larger than that business. In addition to a pharmacy benefits business, CVS also has a health

The latest earnings report published by specialty healthcare company Patterson Companies (NASDAQ: PDCO) impressed not only investors, but also pundits following the stock. On that wave of optimism

Shares of UnitedHealth Group (NYSE: UNH) fell off a cliff last week after the company reported that it is seeing a rise in surgeries. This development will increase its costs and impact its bottom

It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and

Shares of clinical-stage biotech Dice Therapeutics (NASDAQ: DICE) jumped by 37.5% during the first three and a half days of trading this week, according to data provided by S&P Global Market

Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data

There is a difference of opinion about whether the economy is headed for a recession or perhaps already coming out of one, depending on what metrics are used. That can be confusing for investors

A year ago, Pfizer (NYSE: PFE) was soundly beating the market, racking up highly impressive sales thanks to its COVID-19 products. But with the pandemic no longer a global health crisis per guidance

If you're investing in dividend stocks, you should prioritize investments that increase their payouts. That way, the recurring dividend income you receive can potentially stay ahead of inflation.

A

Investors looking to participate in the stock market have a multitude of options, and it can sometimes be hard to separate the wheat from the chaff. But some companies look especially attractive

Nvidia attracted plenty of investor excitement this year thanks to the increased hype surrounding artificial intelligence (AI). That excitement was enough to help it exceed a $1 trillion market cap

In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:

Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at

Shares of Patterson Companies (NASDAQ: PDCO) were up 14.7% Wednesday afternoon after rising as much as 28.3%, hitting a 52-week high of $32.82. The healthcare company, which makes products and

Over the last couple of weeks, Cathie Wood's ARK Innovation ETF has been busy buying shares of gene-editing biotech Intellia Therapeutics (NASDAQ: NTLA). She's also been selling some shares of

Over time, stocks with growing dividends and high returns on invested capital (ROICs) have tended to outperform their peers. By highlighting these qualities -- plus a payout ratio below 50% --

Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching

The primary objective of dividend growth investing is to build an investment portfolio that can provide an investor with reliable and growing streams of passive income. The dividends can be used